Literature DB >> 12740679

Mitral valve vegetation and cerebral emboli in a primary antiphospholipid syndrome patient who had hepatitis C virus infection: report of a case and review of the literature.

O N Pamuk1, N Cakir, M Soy, M Aktoz, Y Celik, O Akdemir.   

Abstract

We report the case of 36-year-old woman who came to us with a history of recurrent miscarriages and who was later diagnosed as having primary antiphospholipid syndrome (PAPS) and chronic hepatitis C virus (HCV) infection. The patient was referred to us with generalised seizures; cranial MRI revealed multiple embolic infarcts in both frontal lobes and a focal cortical infarct in the left frontoparietal lobe. Her echocardiography showed mitral valve vegetation and insufficiency. The patient was put on oral anticoagulant therapy and during her 8-month follow-up period no thrombotic events occurred. We report this case because it was the first in which PAPS, valvular disease, a cerebral embolic event and HCV infection were coexistent in the same patient. We also review other cases in which there was valvular vegetation and a cerebral ischaemic event associated with PAPS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740679     DOI: 10.1007/s10067-002-0662-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  3 in total

1.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 2.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

Review 3.  The Heart and APS.

Authors:  Mary-Carmen Amigo
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.